Capital Guardian Trust’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Capital Guardian Trust’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	$47.8M	Buy	+1,090,679	New	+$61.5M	0.64%	64

Other funds holding BHVN

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Capital Guardian Trust's BHVN Position: Q2 2019 in Review

Capital Guardian Trust opened a new position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2019: 1,090,679 shares worth $47.8M. The stake represents 0.64% of the portfolio and ranks #64 among its holdings.

197 funds tracked by Wall St. Rank hold BHVN as of Q2 2019.

Capital Guardian Trust held 1,090,679 shares of Biohaven Pharmaceutical Holding Company Ltd. worth $47.8M as of Q2 2019.
Biohaven Pharmaceutical Holding Company Ltd. was a new Capital Guardian Trust position in Q2 2019.
Biohaven Pharmaceutical Holding Company Ltd. made up 0.64% of Capital Guardian Trust's portfolio in Q2 2019, its #64 holding.
197 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2019.

Based on Capital Guardian Trust's 13F filing for Q2 2019, filed 14 Aug 2019.